Crowley John F

About Crowley John F

John F. Crowley is an American biopharmaceutical executive and board leader best known for his long-standing leadership in rare-disease biotechnology companies. His most notable recent role is Executive Chairman of Amicus Therapeutics, where he previously served in top operating roles including Chairman and Chief Executive Officer. His career has been closely tied to the development of therapies for genetically driven diseases with significant unmet medical need, especially lysosomal storage disorders. ([ir.entradatx.com](https://ir.entradatx.com/static-files/984b8396-3db7-40d4-9dfd-fae67cf4c967?utm_source=openai)) Earlier in his career, Crowley co-founded Novazyme Pharmaceuticals and served as its President and Chief Executive Officer until the company was acquired by Genzyme in 2001. After that transaction, he continued to work on Pompe disease programs at Genzyme Therapeutics as Senior Vice President, helping advance drug development efforts in a highly specialized area of rare disease medicine. This experience gave him a strong reputation for building biotech ventures, guiding preclinical and clinical programs, and navigating strategic transitions in life sciences. ([ir.entradatx.com](https://ir.entradatx.com/news-releases/news-release-details/entrada-therapeutics-appoints-john-f-crowley-board-directors?utm_source=openai)) At Amicus, Crowley helped guide the company’s growth around therapies for Fabry disease, Pompe disease, and other orphan conditions. Company materials highlight his role in governance, strategy, and portfolio progression, as well as his ability to move scientific concepts toward clinical and ultimately commercial opportunities. He is widely viewed as both an entrepreneur and an operator, with hands-on experience in public biotech companies and a track record in rare-disease development. ([ir.amicusrx.com](https://ir.amicusrx.com/news-releases/news-release-details/amicus-therapeutics-board-directors-names-chief-executive?utm_source=openai)) Crowley also serves on the boards of Entrada Therapeutics and Intellia Therapeutics. Those companies describe him as bringing relevant experience from founding biotech companies that advanced programs from preclinical to clinical development, and in some cases to a commercialized medicine. Intellia also notes that he has served on additional biotech boards, reinforcing his standing as an experienced governance professional in the U.S. public life sciences market. ([ir.entradatx.com](https://ir.entradatx.com/news-releases/news-release-details/entrada-therapeutics-appoints-john-f-crowley-board-directors?utm_source=openai)) Beyond his corporate roles, Crowley is associated with capital formation, team leadership, and long-term decision-making in regulated innovation environments. His background makes him a strong fit for NYSE/NASDAQ biotechnology governance, especially where the board must balance scientific risk, clinical execution, and value creation in rare disease therapeutics.